AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS

On December 20, 2016, our board of directors appointed Dr. Emil Engel to the Company’s Advisory Board.

Dr. Emil Engels MD, MBA, CPC

Dr. Emil Engels, MD, MBA, CPC received his medical degree from Yale University and completed his residency at Brigham and Women’s Hospital in Boston, Massachusetts. He completed additional fellowship in cardiac anesthesia at Harvard Medical School, and is currently a Partner at Fairfax Anesthesiology Associates and American Anesthesiology of Virginia.

Dr. Engels earned an MBA from the University of Tennessee. He also holds a Lean Six-Sigma Certification and is a Certified Professional Coder.  He also serves as Corporate Compliance Officer for Fairfax Anesthesiology Associates, and serves on the Mednax Corporate Coding and Compliance Committees and the following ASA committees: Committee of Economics and the Committee on Large Group Practices. He is currently the President-Elect of the Virginia Society of Anesthesiologists (VSA). In addition, Dr. Engels participates on the Medicare Carrier Advisory Committee for Novitas.

About AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM)

AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson’s disease, Alzheimer’s disease, restless leg syndrome (RLS) and Crohn’s disease.

AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Recent Trading Information

AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) closed its last trading session up +1.44 at 11.74 with shares trading hands.